Jantar is a clinical R/D company in the field of chronic rhinosinusitis. Its asset is dicholine succinate for which clinical proof-of-concept has been established. DISU represents a differentiated new drug with strong safety, rapid efficacy and clear potential for global consumer health leadership.

Strategic Board & Transaction Advisory for Life Sciences Dr. Claudia Ulbrich advises growth-stage biotech and medtech companies as an independent board member and strategic advisor. She has more than 25 years experience as CEO, board member and advisor in private and public companies.

Business Strategy and Development Partner in the Life Science Industry with over 30 years of experience in Pharma, Pharma Chemistry and Biotech.